AU2022275300A1 - Nlrp3 inhibitors - Google Patents

Nlrp3 inhibitors Download PDF

Info

Publication number
AU2022275300A1
AU2022275300A1 AU2022275300A AU2022275300A AU2022275300A1 AU 2022275300 A1 AU2022275300 A1 AU 2022275300A1 AU 2022275300 A AU2022275300 A AU 2022275300A AU 2022275300 A AU2022275300 A AU 2022275300A AU 2022275300 A1 AU2022275300 A1 AU 2022275300A1
Authority
AU
Australia
Prior art keywords
methyl
triazin
phenyl
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022275300A
Other languages
English (en)
Inventor
Lea Aurelie BOUCHE
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina MESCH
Andreas Michael TOSSTORFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2022275300A1 publication Critical patent/AU2022275300A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2022275300A 2021-05-12 2022-05-10 Nlrp3 inhibitors Pending AU2022275300A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21173452.0 2021-05-12
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21209447.8 2021-11-22
EP21215859.6 2021-12-20
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
AU2022275300A1 true AU2022275300A1 (en) 2023-09-21

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275300A Pending AU2022275300A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Country Status (25)

Country Link
US (1) US20240208928A1 (https=)
EP (2) EP4337652B1 (https=)
JP (1) JP2024517917A (https=)
KR (1) KR20240007152A (https=)
AR (1) AR125818A1 (https=)
AU (1) AU2022275300A1 (https=)
BR (1) BR112023023527A2 (https=)
CA (1) CA3214626A1 (https=)
CL (1) CL2023003312A1 (https=)
CO (1) CO2023016204A2 (https=)
CR (1) CR20230529A (https=)
DK (1) DK4337652T3 (https=)
ES (1) ES3031704T3 (https=)
FI (1) FI4337652T3 (https=)
HR (1) HRP20250632T1 (https=)
HU (1) HUE071498T2 (https=)
IL (1) IL307188A (https=)
LT (1) LT4337652T (https=)
MA (1) MA64323B1 (https=)
MX (1) MX2023012907A (https=)
PE (1) PE20240126A1 (https=)
PL (1) PL4337652T3 (https=)
RS (1) RS66893B1 (https=)
SI (1) SI4337652T1 (https=)
WO (1) WO2022238347A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
JP2026511027A (ja) * 2023-03-20 2026-04-10 インシリコ メディスン アイピー リミティド Nlrp3インフラマソーム阻害剤及びその使用
WO2024193699A1 (zh) 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
IL324489A (en) 2023-06-29 2026-01-01 Hoffmann La Roche Triazine derivatives as NLRP3 inhibitors
CN121586712A (zh) 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
MX2023012907A (es) 2023-11-08
PL4337652T3 (pl) 2025-07-14
TW202311245A (zh) 2023-03-16
SI4337652T1 (sl) 2025-07-31
RS66893B1 (sr) 2025-07-31
EP4337652B1 (en) 2025-04-09
LT4337652T (lt) 2025-06-25
EP4609865A3 (en) 2025-10-29
KR20240007152A (ko) 2024-01-16
JP2024517917A (ja) 2024-04-23
DK4337652T3 (da) 2025-06-10
AR125818A1 (es) 2023-08-16
BR112023023527A2 (pt) 2024-01-30
CA3214626A1 (en) 2022-11-17
MA64323B1 (fr) 2025-06-30
ES3031704T3 (en) 2025-07-10
EP4609865A2 (en) 2025-09-03
PE20240126A1 (es) 2024-01-22
EP4337652A1 (en) 2024-03-20
US20240208928A1 (en) 2024-06-27
FI4337652T3 (fi) 2025-06-20
HUE071498T2 (hu) 2025-09-28
WO2022238347A1 (en) 2022-11-17
HRP20250632T1 (hr) 2025-07-18
CR20230529A (es) 2023-12-04
IL307188A (en) 2023-11-01
CL2023003312A1 (es) 2024-06-21
CO2023016204A2 (es) 2023-12-11

Similar Documents

Publication Publication Date Title
EP4337652B1 (en) Nlrp3 inhibitors
EP4347571B1 (en) Triazine derivatives and their use in the treatment of cancer.
TWI850648B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
US20240409553A1 (en) Heterocyclic nlrp3 inhibitors
US20240279237A1 (en) Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors
TW201107325A (en) Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
MD4649C1 (ro) Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
US11046686B2 (en) Thiadiazole IRAK4 compounds
US20250353830A1 (en) Novel compounds
CN120303272A (zh) Nlrp3的抑制剂
CA3268380A1 (en) TRIAZINONE DERIVATIVES USED AS NLRP3 INHIBITORS
CA3197659A1 (en) New indazole acetylene derivatives
CA2870527A1 (en) Nitrogenated bicyclic aromatic heterocyclic compound
CN117794910A (zh) Nlrp3抑制剂
TWI915553B (zh) 新穎化合物、包含其之組成物以及相關製備方法及醫藥用途
EA052779B1 (ru) Триазиновые производные и их применение в лечении рака
HK40104195A (zh) Nlrp3抑制剂